Intuitive Surgicals: A solid company in to consider buyingIntuitive Surgical, Inc.BATS:ISRGthesharkkeHello, Intuitive Surgicals, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Intuitive develops, manufactures and markets the da Vinci surgical system. The company strives to make surgery more effective, less invasive and easier on surgeons, patients and their families. Da Vinci robotic surgical systems are systems designed to increasing the scale & efficiency of minimal invasive surgery. Intuitive Surgical has demonstrated remarkable growth over the past five years, with significant increases in total revenue, net income and earnings per share. This underscores the company's ability to deliver consistent shareholder value. We see a situation where the total addressable market for this company will continue to grow over the medium and long term. In the Q4 earnings release, Intuitive delivered excellent results with strong performance in procedure growth and both domestic and outside-the-US system placements and utilization rates. The strength of general surgery, particularly in the U.S. and global markets, continues to reinforce the rising adoption of robotic-assisted surgery, a trend we expect to persist. We expect general surgeons to continue preferring robotic assisted surgery hence continue to see a market for intuitive surgical. Surgical practice globally has undergone significant advancements with the advent of robotic systems. In Africa for example, a similar trend is emerging with the introduction of robots into various surgical specialties in certain countries. We noted from Intuitive surgical website that you can now purchase their machinery via their south African business agent with data confirming that the equipment are being used in a number of countries in Africa. While growth in certain procedures—particularly in the U.S. market—may begin to slow as penetration rates approach their peak, we view this risk as limited. The company still has significant untapped potential in international markets, which should sustain attractive growth for some time. Moreover, even in the event of rising competition, we believe high switching costs will protect its market position. Clients would need a compelling reason to shift to alternative systems, given the expense and effort of retraining surgeons and adapting workflows. The recent pullback presents a more attractive entry opportunity, with our medium-term price target of $720 reflecting the company’s solid fundamentals and strong market potential. We maintain a strong buy recommendation at current levels. Attention now turns to the upcoming Q1 2026 earnings release on April 21, 2025, where historical data shows that Intuitive Surgical Inc. has consistently exceeded earnings expectations in each of the past ten quarters. Analysts currently project earnings per share of USD 2.12 for this quarter. From a technical standpoint, the recent correction further supports our bullish outlook, reinforcing our Buy bias both fundamentally and technically. Opportunities Intuitive launched its next-generation platform, which should give significant momentum to system placements in the next few years. Intuitive Surgical is enjoying tremendous success in general surgery, which is now its highest-volume surgical area. The opportunity is particularly attractive internationally. Intuitive's foray into bronchoscopy shows the company isn't resting on its laurels and is willing to look in other areas in need of robotic assistance. Risks to consider We may be seeing the emergence of some competition, particularly for lower-cost procedures. Intuitive's margins have been declining as the company has been investing in its Ion platform and next generation Da Vinci system. Da Vinci robotic surgical systems are systems designed to increasing the scale & efficiency of minimal invasive surgery You can find more details about the financials of the company via links https://www.tradingview.com/symbols/NASDAQ-ISRG/financials-income-statement/ The analyst call as per Tradingview is a BUY with an average price target of $597.35